Cleveland Clinic is a nonprofit, multispecialty academic medical center integrating outpatient and hospital care with research and education for better patient outcomes and experience. More than 4,500 staff physicians and researchers provide services through 20 patient-centered institutes. Cleveland Clinic is a 6,500-bed healthcare system with a main campus in Cleveland, 22 hospitals and over 220 outpatient locations. The health system includes five hospitals in Southeast Florida with more than 1,000 beds, a medical center for brain health in Las Vegas, a sports and executive health center in Toronto, and a 364-bed hospital in Abu Dhabi. Cleveland Clinic London, a 184-bed hospital, opened in March 2022. Cleveland Clinic is recognized in the U.S. and throughout the world for its expertise and care.
Cleveland Clinic Researchers Explore Epigenetic Combo as Immunotherapy Booster
May 16th 2017An epigenetic strategy under study at Cleveland Clinic combines THU, a cytidine deaminase inhibitor, with decitabine and nivolumab (Opdivo) in patients with non-small cell lung cancer. The results of early studies demonstrate that THU may help prime the immune system.
Dr. Bratslavsky on the Evaluation and Management of Kidney Cancer
May 16th 2017Gennedy Bratslavsky, MD, deputy director of Upstate Cancer Center, director of the Robotic Program for all Upstate Campuses, and director of the VHL Clinical Cancer Center, discusses the evaluation and management of kidney cancer.
AR-V7 Predicts Response in Castration-Resistant Prostate Cancer
The presence of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells predicted poorer outcomes for men with castration-resistant prostate cancer assigned to novel hormonal therapies, according to results recently published in the Journal of Clinical Oncology.
Dr. Koyfman on IMRT and SBRT Reirradiation for Head and Neck Cancer
March 16th 2017Shlomo Koyfman, MD, associate staff, radiation oncology, Cleveland Clinic, discusses intensity-modulated radiation therapy (IMRT) and stereotactic body radiotherapy (SBRT) reirradiation for patients with head and neck cancer.
Dr. Abraham on Prevention of Hair Loss for Breast Cancer Chemotherapy
January 20th 2017Jame Abraham, MD, director of the Breast Oncology Program at Taussig Cancer Institute, and co-director of the Cleveland Clinic Comprehensive Breast Cancer Program, discusses a head cooling system that can be used to limit hair loss attributed to chemotherapy treatment for patients with breast cancer.
Dr. Montero Discusses PERTAIN Study in HER2-Positive Breast Cancer
January 9th 2017Alberto J. Montero, MD, Department of Hematology and Oncology at Cleveland Clinic, discusses the PERTAIN study in postmenopausal women with hormone receptor-positive, HER2-positive, locally advanced or metastatic breast cancer. The study looks at the impact of adding pertuzumab (Perjeta) to trastuzumab (Herceptin) in aromatase inhibitor (AI) therapy.
Dr. Koyfman on Risk Categories in the Reirradiation Setting of Recurrent Head and Neck Cancer
December 15th 2016Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses risk categories that stratified patients in a study evaluating intensity-modulated radiation therapy and stereotactic body radiation therapy to determine outcomes in the reirradiation setting for recurrent head and neck cancer.
Dr. Velcheti on Potential of Alectinib in Frontline ALK-Positive NSCLC
October 26th 2016Vamsidhar Velcheti, MD, an assistant professor of Medicine at Cleveland Clinic Lerner School of Medicine, discusses the ALK inhibitor alectinib (Alecensa) and what potential the agent could have in the frontline setting for patients with ALK-positive non–small cell lung cancer (NSCLC). Velcheti shared this insight in an interview during the 2016 OncLive State of the Science Summit on Non–Small Cell Lung Cancer.
The Jury's Still Out on Whole-Brain Radiation Therapy for Brain Metastases
September 20th 2016Despite the fervent advocacy of stereotactic radiosurgery alone, the addition of whole-brain radiation therapy clearly improves local control, decreases distant brain failure, minimizes the need for salvage therapies such as surgery, and, most importantly, decreases neurologic death.
Expert Discusses Evolving Roles of Cabozantinib, Nivolumab in RCC
September 8th 2016Jorge A. Garcia, MD, discusses the final survival data from the phase III METEOR trial, which was the basis for cabozantinib's (Cabometyx's) FDA approval, as well as the role the agent will now play along with nivolumab (Opdivo) in advanced RCC.
Dr. Pennell on Importance of EGFR Testing in NSCLC
August 31st 2016Nathan Pennell, MD, PhD, associate professor of Medicine at Cleveland Clinic, discusses the importance of testing patients with non–small cell lung cancer (NSCLC) to determine if they harbor the EGFR mutation, as well as the agents available to target that genetic abnormality.
Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell Carcinoma
October 19th 2015Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a second-line therapy for metastatic renal cell carcinoma.
Dr. Nazha on Mutational Model to Predict Response to Hypomethylating Agents in MDS
October 7th 2015Aziz Nazha, MD, hematologist, Leukemia Program at the Cleveland Clinic, Taussig Cancer Institute, discusses results of a mutational model to predict response to hypomethylating agents in myelodysplastic syndromes (MDS).
Dr. Carraway on Aza-Nucleoside Combinations in MDS
September 18th 2015Hetty Carraway, MD, Hematology and Oncology, Cleveland Clinic, discusses combination epigenetic therapies including aza-nucleosides and histone deacetylase inhibitors, as well as immunomodulatory therapies, such as lenalidomide for the treatment of myelodysplastic syndromes (MDS).
Dr. Sohal on the Challenges of Standardizing Genomic Profiling and Precision Medicine
September 9th 2015Davendra Sohal, MD, MPH, oncologist and Director of the Clinical Genomics Program at the Cleveland Clinic Taussig Cancer Institute, discusses the feasibility of standardizing genomic profiling and apply precision medicine techniques.
Dr. James Stevenson on Standardized Care Pathways for NSCLC Treatment
September 4th 2015James Stevenson, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute (TCI), discusses the impact of a stage IV non-small-cell lung cancer (NSCLC) care pathway on front-line and maintenance chemotherapy.